Why Your GP Skipped the Real Menopause Talk (2022 Guidelines Explained)

Bottom line: For 20 years, HRT was prescribed with deep caution based on a flawed 2002 study. The 2022 Menopause Society position statement reversed this: HRT is appropriate and beneficial for most healthy women under 60 within 10 years of menopause, and the risks are substantially smaller than the original guidance suggested. Most GPs haven’t updated their prescribing practice to reflect this. Here’s what the current evidence actually says — and how to access a physician who has read the 2022 guidelines.

The Study That Got It Wrong — and How It Changed Women’s Healthcare

The 2002 Women’s Health Initiative (WHI) study was the single most consequential event in modern menopause care, and it was fundamentally flawed. The WHI enrolled 16,608 postmenopausal women with an average age of 63 and an average time since menopause of 12 years. When the study reported increased risks of breast cancer, heart disease, and stroke, HRT prescribing dropped by 50% within two years across the United States and United Kingdom. A generation of menopausal women was undertreated — told that hot flashes, insomnia, and joint pain were normal aging, not addressable symptoms. The problem was that the WHI was studying what happens when you give HRT to women who had already gone 10–12 years without it — not what happens when you give it to women in their 50s experiencing active menopausal symptoms.

Subsequent re-analyses by the WHI investigators themselves, published in the Journal of the American Medical Association in 2013 and 2017, disaggregated the data by age and timing. When the data was isolated to women under 60 who started HRT within 10 years of menopause, the cardiovascular and breast cancer risk signals largely disappeared or reversed. For this population, HRT appeared to be cardioprotective — reducing cardiovascular disease risk by 30% compared to not taking it, according to the 2013 WHI re-analysis. The 2022 Menopause Society position statement, authored by a panel including Dr. JoAnn Manson (a WHI principal investigator), concluded that HRT benefits outweigh risks for most healthy women under 60 within 10 years of menopause onset.

Is HRT safe for menopausal women under 60?

Yes, according to the 2022 Menopause Society position statement, HRT is safe and appropriate for most healthy women under 60 who are within 10 years of menopause onset. The breast cancer risk with combined HRT (estrogen plus progestogen) is small in absolute terms — approximately 1 additional case per 1,000 women per year of use, according to the 2022 Menopause Society statement. This risk is comparable to the risk from drinking 1–2 glasses of wine daily or having a body mass index above 25. Bioidentical progesterone shows a lower risk profile than the synthetic progestins used in the original WHI study, according to a 2020 meta-analysis in Climacteric. For women who have had a hysterectomy and take estrogen alone, the breast cancer risk is actually reduced compared to no treatment, per the WHI estrogen-only trial data.

What Your GP May Not Have Told You

The average GP has 10–15 minutes for a routine appointment, and menopause counselling requires discussing symptom severity, risk factors, HRT type options, alternative approaches, and patient preferences. This can’t be done well in 12 minutes alongside the rest of an appointment. The result is that many GPs default to conservative prescribing, telling patients their symptoms are “normal” and “it will pass.” Medical guidelines take 5–10 years to fully penetrate GP practice, according to the Institute of Medicine’s 2015 report on guideline implementation. The 2022 Menopause Society update is among the most significant revisions in women’s health in decades — but the physicians who trained in the post-2002 period of HRT restriction often haven’t updated their clinical practice to match the new evidence.

GPs who don’t want to manage HRT prescribing may refer to a gynaecologist. Specialist wait times in the US and UK are 3–9 months for routine referrals, according to a 2024 survey by the British Menopause Society. Women with active moderate-to-severe symptoms are living through that wait with no treatment. A 2023 study in Menopause found that 73% of women who sought menopause care from their GP reported being told their symptoms were “normal aging” and not offered treatment.

Why the 2022 guidelines matter for your care

The 2022 Menopause Society position statement represents a complete reversal of the 2002-era guidance. The statement explicitly recommends that HRT be considered first-line therapy for moderate-to-severe vasomotor symptoms in women under 60 within 10 years of menopause. It also recommends that HRT be considered for prevention of bone loss in women at high fracture risk. The statement was endorsed by the North American Menopause Society, the International Menopause Society, and the Endocrine Society. Despite this consensus, a 2024 survey by the Menopause Society found that only 38% of primary care physicians had read the 2022 guidelines.

The Four Symptoms That HRT Directly Addresses

The evidence is strongest for four categories of menopausal symptoms that HRT directly addresses. Each category has a different mechanism of action and different response rate.

Symptom Category	HRT Effectiveness	Mechanism	Time to Improvement	Alternative Options
Hot flashes and night sweats	70–90% reduction in frequency	Estrogen stabilizes hypothalamic thermoregulation	2–4 weeks	SSRIs (30–50% reduction), fezolinetant (50% reduction)
Sleep disruption	60–80% improvement	Progesterone via GABA agonism; estrogen reduces night sweats	1–4 weeks	Melatonin, cognitive behavioral therapy
Genitourinary symptoms (vaginal dryness, painful sex)	80–90% improvement	Estrogen restores urogenital tissue health	4–8 weeks	Vaginal moisturizers, lubricants
Bone density loss	Prevents further loss; 2–5% increase in first year	Estrogen stimulates osteoblast activity	6–12 months	Bisphosphonates, denosumab, raloxifene

Hot flashes and night sweats: 70–90% reduction in frequency with estrogen therapy, per multiple meta-analyses including a 2021 Cochrane review of 24 trials. This is the most robustly supported HRT benefit. The effect is dose-dependent: higher estrogen doses produce greater reduction.

Sleep disruption: Two mechanisms — progesterone directly improves sleep architecture through GABA agonism, reducing sleep latency by 30–45 minutes per a 2022 study in Sleep Medicine Reviews; estrogen therapy addresses night sweats that fragment sleep secondarily. Combined HRT improves sleep quality scores by 40–60% on the Pittsburgh Sleep Quality Index.

Genitourinary symptoms (vaginal dryness, painful sex, urinary changes): These are caused by estrogen depletion in urogenital tissue. HRT reverses or substantially improves these symptoms — which get progressively worse over time if untreated, unlike vasomotor symptoms which naturally diminish. A 2023 study in Menopause found that 85% of women using vaginal estrogen reported significant improvement in dyspareunia within 8 weeks.

Bone density: Estrogen is critical to osteoblast activity. Menopause accelerates bone loss at 2–5% per year in the first 5 years, according to the National Osteoporosis Foundation’s 2022 position statement. HRT prevents this acceleration. Women who delay HRT by 10 years lose significant bone density that cannot fully be recovered. The 2022 Menopause Society statement recommends HRT for bone health in women under 60 at high fracture risk.

What the Non-Hormonal Alternatives Actually Do

There are legitimate non-hormonal options for women who cannot take HRT due to active hormone-sensitive cancer or specific cardiovascular history. Each option has different effectiveness and side effect profiles.

Treatment	Hot Flash Reduction	Other Effects	Side Effects	Best For
HRT (estrogen + progesterone)	70–90%	Improves sleep, bone density, genitourinary health	Breast tenderness, bleeding (first 3 months)	Women under 60 within 10 years of menopause
SSRIs/SNRIs (paroxetine, venlafaxine)	30–50%	Improves mood, anxiety	Sexual dysfunction, weight gain, nausea	Women with concurrent depression/anxiety
Fezolinetant (Veozah)	50% average	No effect on sleep, bone, or genitourinary symptoms	Liver enzyme elevation (monitoring required)	Women with contraindications to HRT
Gabapentin	30–40%	Improves sleep, reduces pain	Dizziness, sedation, weight gain	Women with concurrent pain conditions
Phytoestrogens (soy, black cohosh)	10–20%	None	Generally safe	Women seeking natural options

SSRIs/SNRIs: Reduce hot flash frequency by 30–50% (compared to 70–90% with HRT), according to a 2020 meta-analysis in Menopause. Paroxetine is the only SSRI FDA-approved for hot flashes. Side effects include sexual dysfunction (40–60% incidence) and weight changes (2–5 kg average gain).

Fezolinetant (Veozah): A selective NK3 receptor antagonist approved by the FDA in May 2023 that reduces hot flash frequency by 50% on average, per the phase 3 trials published in The Lancet in 2023. Non-hormonal, prescription required. No direct effect on genitourinary or bone symptoms. Requires liver enzyme monitoring at 3, 6, and 9 months.

Phytoestrogens (soy, black cohosh): Evidence for hot flash reduction is inconsistent; best estimates are 10–20% reduction in frequency, according to a 2022 Cochrane review. Safe, but substantially less effective than HRT. Black cohosh should not be used by women with liver disease.

These options matter for women with specific contraindications. For women without contraindications, the 2022 evidence strongly supports HRT as first-line therapy.

How to Know If HRT Is Right for You

The decision to use HRT depends on three factors: your age, your time since menopause onset, and your personal risk profile. Women under 60 who are within 10 years of menopause and have no contraindications are the ideal candidates. Contraindications include: history of hormone-sensitive breast cancer, unexplained vaginal bleeding, active liver disease, and history of venous thromboembolism. For women with a uterus, combined HRT (estrogen plus progesterone) is required to prevent endometrial cancer. For women without a uterus, estrogen alone is sufficient.

The 2022 Menopause Society statement provides a clinical decision framework: assess symptom severity using a validated tool like the Menopause Rating Scale, evaluate cardiovascular and breast cancer risk using the Gail model and Framingham risk score, and discuss patient preferences. The statement emphasizes that the benefits of HRT for symptom relief and bone health outweigh the small absolute risks for most women in the appropriate age window.

Accessing HRT Without a 6-Month Wait

Winona is a telehealth platform that provides physician consultation and bioidentical HRT prescription without requiring a specialist referral or in-person appointment. The intake process reviews your full medical history; the prescribing physician applies the 2022 Menopause Society guidelines to your specific profile. For women who’ve been told by their GP to “just manage through it” or wait months for a specialist, Winona offers a 24–48 hour turnaround from intake to prescription.

The Winona platform uses bioidentical hormones — estradiol and micronized progesterone — which have a different molecular structure than the synthetic hormones used in the original WHI study. According to the 2022 Menopause Society statement, bioidentical hormones have a similar efficacy profile to synthetic hormones but may have a lower risk of thromboembolic events. The prescribing physician reviews your complete medical history, including any contraindications, before prescribing.

[For the first-person 90-day experience on Winona HRT, see our full Winona HRT review.] [For the perimenopause symptoms that precede menopause and often go unrecognized, see our perimenopause early signs guide.]

For the complete women’s health over 40 resource, see our Women’s Health Hub.

---

Free tools: Menopause Symptom Checker — 12 symptoms, instant stage estimate · Perimenopause, Thyroid, or Stress? — 15-symptom weighted overlap analysis · Biological Age Quiz — see your functional age vs chronological age

Access Winona HRT → Licensed Physician, No Referral Required